Your Health, We Care
February 13, 2015: The U.S. Food and Drug Administration (FDA) approved Lenvatinib for the treatment of differentiated thyroid cancer (DTC).
May 13, 2016: The U.S. Food and Drug Administration (FDA) approved Lenvatinib for the treatment of advanced renal cell carcinoma (RCC).
August 16, 2018: The U.S. Food and Drug Administration (FDA) approved Lenvatinib for first-line treatment of unresectable hepatocellular carcinoma (HCC).
September 17, 2019: The U.S. Food and Drug Administration (FDA) approved the combination of Keytruda (Pembrolizumab) and Lenvatinib for the treatment of certain types of endometrial carcinoma.
July 22, 2021: The U.S. Food and Drug Administration (FDA) approved the combination of Keytruda (Pembrolizumab) and Lenvatinib for the treatment of certain types of advanced endometrial carcinoma.
August 11, 2021: The U.S. Food and Drug Administration (FDA) approved the combination of Keytruda (Pembrolizumab) and Lenvatinib for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
On July 22, 2021, Merck & Co., Inc. and Eisai Co., Ltd. jointly announced th···【more】
Release date：2026-01-05Recommended：43
Merck & Co., Inc. and Eisai Co., Ltd. jointly announced today that the U.S. ···【more】
Release date：2026-01-05Recommended：39
